 |
|
|
| |
Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: Week 49 results from a phase 3 trial
|
| |
| |
EACS 2023 Oct 18-21 Warsaw
Rosie Mngqibisa1; Ilsiyar Khaertynova2; Princy N. Kumar3; Andrew Carr4; Shariq Haider5; Ying Zhang6;
Todd Correll6; Ernest Asante-Appiah6; Wayne Greaves6*
1Enhancing Care Foundation, King Edward Hospital, Durban, South Africa; 2Kazan State Medical Academy, Kazan, Russia; 3Georgetown University, Washington, DC, USA; 4St Vincent's Hospital, Sydney, NSW, Australia; 5McMaster University, Hamilton, ON, Canada; 6Merck & Co., Inc., Rahway, NJ, USA
*Presenting author
An employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, at the time of the study
|
| |
|
|
|
|
|
